title: Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer.
abstract: Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer. The aim of this study was to evaluate the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited. 5-FU was administered over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of 1,000 mg/m2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates that the combination of 5-FU/heptaplatin combination is less active but tolerated in patients with advance gastric cancer.
authors.affiliation: Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. yjmin@uuh.ulsan.kr
authors.forename: Young Joo
authors.initials: YJ
authors.lastname: Min
authors.forename: Sung-Jo
authors.initials: SJ
authors.lastname: Bang
authors.forename: Jung Woo
authors.initials: JW
authors.lastname: Shin
authors.forename: Do Ha
authors.initials: DH
authors.lastname: Kim
authors.forename: Jae Hoo
authors.initials: JH
authors.lastname: Park
authors.forename: Gyu Yeol
authors.initials: GY
authors.lastname: Kim
authors.forename: Byung Kyun
authors.initials: BK
authors.lastname: Ko
authors.forename: Dae Hwa
authors.initials: DH
authors.lastname: Choi
authors.forename: Hong Rae
authors.initials: HR
authors.lastname: Cho
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008314:Malonates / Q000008:administration & dosage*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D008314:Malonates; D009944:Organoplatinum Compounds; C090717:SKI 2053R; D005472:Fluorouracil